Knee and shoulder arthritis/torn rotator cuffs 16 months after stem cell therapy by Dr Harry Adelson
Mike discusses his results 16 months after stem cell therapy for his arthritic knees and shoulders and torn rotator cuffs by Dr Harry Adelson at http://www.docerecl...

By: Harry Adelson, N.D.

Read the rest here:
Knee and shoulder arthritis/torn rotator cuffs 16 months after stem cell therapy by Dr Harry Adelson - Video

Successful Fetal Stem Cell Therapy in Kyiv, Ukraine at EmCell via PlacidWay
Watch Daniel #39;s testimonial after undergoing successful Fetal Stem Cell Therapy at EmCell in Kyiv, Ukraine.

By: placidways

View post:
Successful Fetal Stem Cell Therapy in Kyiv, Ukraine at EmCell via PlacidWay - Video

La Jolla, CA (PRWEB) June 17, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases, today announced their newest clinical study for Multiple Sclerosis. StemGenex believes that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.

This clinical study is bringing to the field a new, unique type of stem cell therapy that has the possibility of being more effective than other stem cell treatments currently available. Patients who receive stem cell treatment through StemGenex for Multiple Sclerosis will receive StemGenex multiple administration protocol. This consists of four targeted administration methods of the stem cells to deliver the necessary amount of stem cells past the blood brain barrier.

Principal Investigator Dr. Jeremiah McDole, Ph.D. stated, "Currently available drugs for multiple sclerosis do not halt disease progression or aid in the repair of established damage. We strive to provide regenerative medicine applications that address this critical, underlying issue. While patients experience positive clinical outcomes as a result of stem cell treatment, large, rigorously performed studies are desired in order to guide our best efforts for future development. The study we are conducting is designed to provide us with this essential data."

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval. According to StemGenex Director of Patient Advocacy, Joe Perricone, It is important patients have access to top-tier stem cell treatment. By providing access to registered clinical studies through The National Institutes of Health, we are providing patients with the ability to choose a stem cell treatment center with the highest standard of care.

Rita Alexander, founder and president of StemGenex, stated, This is the first of many stem cell clinical studies to come and a positive step for the more than 2 million people around the world suffering with Multiple Sclerosis. The average lifetime cost of current standard of care treatment per MS patient is $1.2 million. The human cost of the disease including pain and suffering endured by MS patients, the profound impact on families and the loss of their ability to contribute to society is without question immeasurable. Dr. McDoles research background in neuroimmunology is certainly an asset in our effort to change the course of neurological diseases.

Stem cell treatment studies are currently being offered by StemGenex to patients diagnosed with Multiple Sclerosis and other degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Parkinsons and Alzheimers disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact(at)stemgenex(dot)com

Read this article:
StemGenex Announces New Stem Cell Clinical Study for Multiple Sclerosis

Scientists in the University of Connecticut's Technology Incubation Program have identified a novel approach to treating multiple sclerosis (MS) using human embryonic stem cells, offering a promising new therapy for more than 2.3 million people suffering from the debilitating disease.

The researchers demonstrated that the embryonic stem cell therapy significantly reduced MS disease severity in animal models, and offered better treatment results than stem cells derived from human adult bone marrow.

The study was led by ImStem Biotechnology Inc. of Farmington, Conn., in conjunction with UConn Health Professor Joel Pachter, Assistant Professor Stephen Crocker, and Advanced Cell Technology (ACT) Inc. of Massachusetts. ImStem was founded in 2012 by UConn doctors Xiaofang Wang and Ren-He Xu, along with Yale University doctor Xinghua Pan and investor Michael Men.

"The cutting-edge work by ImStem, our first spinoff company, demonstrates the success of Connecticut's Stem Cell and Regenerative Medicine funding program in moving stem cells from bench to bedside," says Professor Marc Lalande, director of the UConn's Stem Cell Institute.

The research was supported by a $1.13 million group grant from the state of Connecticut's Stem Cell Research Program that was awarded to ImStem and Professor Pachter's lab.

"Connecticut's investment in stem cells, especially human embryonic stem cells, continues to position our state as a leader in biomedical research," says Gov. Dannel P. Malloy. "This new study moves us one step closer to a stem cell-based clinical product that could improve people's lives."

The researchers compared eight lines of adult bone marrow stem cells to four lines of human embryonic stem cells. All of the bone marrow-related stem cells expressed high levels of a protein molecule called a cytokine that stimulates autoimmunity and can worsen the disease. All of the human embryonic stem cell-related lines expressed little of the inflammatory cytokine.

Another advantage of human embryonic stem cells is that they can be propagated indefinitely in lab cultures and provide an unlimited source of high quality mesenchymal stem cells -- the kind of stem cell needed for treatment of MS, the researchers say. This ability to reliably grow high quality mesenchymal stem cells from embryonic stem cells represents an advantage over adult bone marrow stem cells, which must be obtained from a limited supply of healthy donors and are of more variable quality.

"Groundbreaking research like this furthering opportunities for technology ventures demonstrates how the University acts as an economic engine for the state and regional economy," says Jeff Seemann, UConn's vice president for research.

The findings also offer potential therapy for other autoimmune diseases such as inflammatory bowel disease, rheumatoid arthritis, and type-1 diabetes, according to Xu, a corresponding author on the study and one of the few scientists in the world to have generated new human embryonic stem cell lines.

Excerpt from:
Embryonic stem cells offer new treatment for multiple sclerosis

Global Stem Cell Therapy Industry Pipeline Analysis 2020
Stem Cell Therapy Industry @ http://bit.ly/1qkbHjQ.

By: Ashley Harvey

More:
Global Stem Cell Therapy Industry Pipeline Analysis 2020 - Video

Stem Cell Therapy in South Korea
When traditional treatments fail, Stem Cell Therapy in South Korea offers hope to worldwide patients.

By: placidways

Go here to read the rest:
Stem Cell Therapy in South Korea - Video

Patient Testimonial: Stem cell therapy for Multiple Sclerosis
http://www.placidway.com/profile/1617/ - Stem cell therapy in Switzerland was effective for 44 year old patient who had multiple sclerosis. He explains how the side effects started to diminish...

By: placidways

More here:
Patient Testimonial: Stem cell therapy for Multiple Sclerosis - Video

Lumbar disc pain one year after stem cell therapy by Dr Harry Adelson
Lisa describes her outcome one year after having bone marrow stem cells injected into her degenerated and dehydrated lumbar discs by Dr Harry Adelson http://www.docereclinics.com.

By: Harry Adelson, N.D.

Read the rest here:
Lumbar disc pain one year after stem cell therapy by Dr Harry Adelson - Video

Contact Information

Available for logged-in reporters only

Newswise LOS ANGELES (June 17, 2014) Stem cell therapy for cardiovascular disease isnt a medical pipe dream its a reality today, although patients need to better understand the complex science behind these experimental treatments, according to the chief of Cardiology for the Cedars-Sinai Heart Institute.

In a 17-minute TEDxGrandForks talk now available on YouTube.com, Timothy D. Henry, MD, known for his innovative work in developing stem cell treatments for advanced heart disease patients, said he understands why so many are confused about the latest scientific findings.

Most people today get our information from sound bites, and the issues surrounding stem cells are too complex to be fully explained in a single catchy phrase, Henry said, adding, We have far too much controversy about stem cells and far too much hype.

Stem cell science has become a political dividing line with many opposing research into stem cells derived from human embryos, Henry said. However, he said, todays leading-edge clinical research focuses on stem cells derived from adults that can be scientifically programmed to become a specialized cell, such as a heart cell or a brain cell, thereby avoiding the ethical questions involved in embryonic research.

Very few of the cells we give actually become muscle or actually become blood vessels, Henry said. What they do is increase growth factors and encourage natural cells in the body to generate new, healthy tissue.

The Cedars-Sinai Heart Institute, directed by Eduardo Marbn, MD, PhD, is a world leader in studying the use of stem cells to regenerate heart muscle in patients who have had heart attacks. In 2009, Cedars-Sinai physicians conducted the first infusion of stem cells into heart attack patients, using stem cells grown from the patients own heart tissue. The resulting study, published in February 2012 in The Lancet, showed that patients who underwent the stem cell procedure experienced a significant reduction in the size of the scar left behind by a heart attack. Patients also experienced a sizable increase in healthy heart muscle following the experimental stem cell treatments.

Currently, Henry is co-directing a new stem cell study with Raj Makkar, MD, director of Interventional Cardiology. The national trial, called ALLSTAR, uses heart cells from unrelated donors in an effort to reverse lasting tissue damage after a heart attack.

During his talk, Henry also expressed concern for patients who might be taken advantage of by unscrupulous clinics outside of the United States that offer stem cell cures for everything from neurological diseases to baldness. Patients also need to understand that stem cell science has a long way to go before regenerative medicine treatments are widely available.

Visit link:
Stem Cell Expert Explains How Experimental Regenerative Medicine Therapies Can Regrow Damaged Heart Muscle

By Ian Dipple Wednesday 18 June 2014 Updated: 18/06 11:28

REDDITCH residents have been urged to join the bone marrow register to help the fight against blood cancer.

Anthony Nolan and Redditch MP Karen Lumley have joined forces for the appeal. For the first time the charity has mapped the bone marrow register across the UK by local area.

In Redditch there are more than 562 people willing to donate their stem cells or bone marrow to save the life of a stranger.

However it is well below the average of 796 per Parliamentary constituency and is ranked 467th out of 650.

Two thirds of UK patients in need of a transplant will not find a matching donor from their family. Anthony Nolan helps them find an unrelated donor but can currently only match half of all requests.

Mrs Lumley said: "I want to see many more of my constituents join this fight. Im hunting for more crusaders to sign up today, so we can fight blood cancer together. It is something truly heroic to give a stranger a second chance at life. This is why Im proud to champion this cause to my constituents."

Ann OLeary, head of register development at Anthony Nolan, added: "Donating is an incredibly selfless thing to do and will give someone with blood cancer their best chance at survival."

Anyone aged 16 to 30 and in good health can join the bone marrow register. It involves filling out a simple online form and spitting into a tube.

Visit http://www.anthonynolan.org/superhero for more information.

Read more from the original source:
MP calls for bone marrow champions

It's possible to alter genetic material of stem cells to provide HIV resistance A DNA sequence can be removed from the cells and replaced with another The replacements can be taken from people with natural HIV resistance These altered stem cells can then be used to create HIV-resistant white blood cells

By Emma Innes

Published: 07:57 EST, 11 June 2014 | Updated: 12:03 EST, 11 June 2014

141 shares

9

View comments

HIV could be cured by genetically editing stem cells, researchers believe.

U.S. scientists say they have already demonstrated that it is possible to alter the genetic material of some stem cells.

This in turn provides HIV resistance, they report.

A new 'genome editing' technique could be the key to curing HIV. Image shows HIV in human tissue

Continue reading here:
Could 'editing' genes be the key to curing HIV? Giving patients altered blood cells could make them resistant to the ...

Stemologica
Researchers have verified that when included in our skin creams, the Uttwiler Sptlauber Swiss apple stem cells will communicate with you have skin #39;s stem ce...

By: Jordan Kaleb

View original post here:
Stemologica - Video

Obesity Weight (Stem Cell Therapy)
The subject matter of this video Obesity Weight.

By: Mohammad Sadique

View original post here:
Obesity & Weight (Stem Cell Therapy) - Video

Stem cell therapy | stem cells laboratory chip osteoarthritis
http://www.arthritistreatmentcenter.com A 3 D lab chip for osteoarthritis... learn more next... Living human cartilage grown on lab chip In Business Standard...

By: Nathan Wei

See the original post:
Stem cell therapy | stem cells laboratory chip osteoarthritis - Video

A.P.REYES, MD ~U.S.SENATOR, LEGALIZING STEM CELL THERAPY IN U.S.A.
I created this video with the YouTube Slideshow Creator (http://www.youtube.com/upload)

By: Arturo Reyes

Here is the original post:
A.P.REYES, MD ~U.S.SENATOR, LEGALIZING STEM CELL THERAPY IN U.S.A. - Video

SUNNYVALE, CA and JOHNSTOWN, CO--(Marketwired - Jun 11, 2014) - Spinal Kinetics, the designer and manufacturer of the M6 Artificial Disc, and Kenneth A. Pettine, MD, a leading spine surgeon in northern Colorado, announced completion of the initial series of M6-C implantsas part of a US FDA Clinical Trial at Arte Surgical Center in Johnstown, Colorado.To date, four patients have received the innovative artificial disc at Arte and are among the first treated nationwide.

Dr. Pettine is the only surgeon in Colorado enrolling for the FDA trial and one of only a select number of centers in the US.The trial compares single-level cervical disc replacement to single-level cervical fusion.The M6-C artificial disc represents next generation technology in artificial cervical disc design. "We are very excited to participate in this important clinical trial," said Dr. Kenneth Pettine, M6-C Clinical Trial Investigator and co-Founder of Arte Surgical Center and The Spine Institute at Rocky Mountain Associates in Orthopedic Medicine (Johnstown, CO)."The M6-C has established a phenomenal track record overseas, and we are happy to finally bring this advancement to our patient base here in the US for this clinical study."

The M6-C artificial cervical disc is designed to help patients suffering from degenerative disc disease of the spine, a common cause of chronic neck and arm pain. The M6 technology provides an alternative to spinal fusion and is designed to restore natural physiologic motion to the spine. The M6 is the only artificial disc that replicates the anatomic structure and biomechanics of a natural disc by incorporating both an artificial nucleus and annulus.

"Spinal Kinetics is proud to collaborate with Dr. Kenneth Pettine at the Spine Institute and the team at Arte Surgical Center on this important milestone event," said Tom Afzal, President and CEO of Spinal Kinetics, Inc."Spine surgeons and patients across the US have asked for access to this leading edge disc technology, and we are excited to start the process toward FDA approval by working with key Surgeon/Investigators like Dr. Pettine and innovative Spine Centers like Arte."

Introduced internationally in 2006, M6 technology has quickly become the market leader in Europe and other international markets and is available in over 27 countries worldwide. With approximately 30,000 implants to date, the M6 has become the disc of choice among leading spine surgeons around the world.In the U.S., Spinal Kinetics has successfully completed an FDA approved pilot study of the M6-C and subsequently received approval from the FDA to initiate the current clinical trial.

For more information on potential enrollment in the M6-C Clinical Trial, please contact Kira Sniff at ksniff@rmaortho.com, or (970) 669-8881 ext 229.

About Degenerative Disc Disease Between adjacent vertebra throughout the spine is an intervertebral disc; a shock-absorbing pillow that helps maintain proper spacing, stability, and motion within the spine.Each disc has a fibrous outer band called the annulus fibrosus that encases a central, gel-like substance called the nucleus pulposus.The nucleus and annulus work together to absorb shock, help stabilize the spine, and provide a controlled range of motion between adjacent vertebra.Often brought on by aging, the spine begins to show signs of wear and tear and the discs can dry out and shrink.This degenerative process can put pressure on the spinal cord and nerves and may cause neck, arm and back pain and other painful conditions such as spinal stenosis or a herniated disc.

About Spinal Kinetics Founded in 2003, Spinal Kinetics is a privately held medical device company focused on developing innovative and practical solutions for treatment of diseases of the spine. The M6-C cervical and M6-L lumbar artificial discs have rapidly established themselves among the leading artificial discs available due to their unique biomechanical properties that replicate the motion of a natural disc.The company is located in Sunnyvale, California.

About Kenneth A. Pettine, MD Dr. Kenneth Pettine co-founded The Spine Institute at Rocky Mountain Associates in Orthopedic Medicine. He has an extensive background in spinal surgery, research, and rehabilitation. Dr. Pettine is a board certified fellowship trained spine surgeon.He is the recipient of numerous honors, a distinguished speaker at national and international symposiums, and the author of nearly 20 research publications. He has been the principal investigator for 16 FDA studies involving non-fusion implants, biologics, and stem cells. For information on Dr. Pettine and The Spine Institute visit http://www.spinerevolution.com

About Arte Surgical Center Arte is a pain management and orthopedic/ spine ambulatory surgical facility in Johnstown, CO, that is licensed and joint commission accredited. We provide our patients with quality outpatient and inpatient surgical care in a safe and friendly environment. For information on the Arte Surgical Center, please visit http://www.aretesurgicalcenter.com

See original here:
Spinal Kinetics and Dr. Kenneth Pettine Initiate US FDA Clinical Trial of M6(R)-C Artificial Cervical Disc at Arete ...

16.06.2014 - (idw) Universitt Basel

T cells use a novel mechanism to fight leukemia. They may recognize unique lipids produced by cancer cells and kill tumor cells expressing these lipid molecules. A study conducted by researchers at the University of Basel shows that a tumor-associated lipid stimulates specific T cells, which efficiently kill leukemia cells both in vitro and in animal models. The results have been published in the Journal of Experimental Medicine. Leukemias are cancer diseases affecting blood cells . Acute leukemias prevent development of normal bold cells and thereby are severe life-threatening diseases. Current therapy for acute leukemias is based on chemotherapy that eradicates tumor cells followed by bone-marrow stem cell transplantation that reconstitutes the patient with healthy blood cells. In some cases, leukemia cells survive this treatment and start to re-grow. A major aim of many studies is finding novel and efficient ways to detect and eradicate leukemia cells before a second outbreak of the disease.

More punch against tumor cells

T lymphocytes are major contributors to fight against leukemias. T cells may recognize and become activated by tumor-specific protein antigens in some instances produced in large amounts only by tumor cells. These protein antigens are also called tumor-associated antigens (TAA) and stimulate specific T cells, which in turn kill leukemia cells. However, protein TAA accumulation can be drastically reduced by variant leukemia cells and some TAA may change their structure, thus preventing recognition by T cells and facilitating tumor immune evasion.

Prof. Gennaro De Libero and his team from the Department of Biomedicine at the University of Basel has identified a new approach that might help to make the immune system more efficient in recognizing leukemia cells. His research team is studying T cells that specifically recognize lipid antigens since several years. Together with colleagues in Italy, China and Singapore, the Swiss team has identified a new lipid that accumulates in leukemia cells and that stimulates specific T cell responses. The new lipid methyl-lysophosphatidic acid (mLPA) is very abundant in several forms of human leukemias and is the first example of a lipid TAA.

The published study also shows that it is possible to isolate human T cells that specifically recognize and kill mLPA-expressing leukemia cells in in vitro tests. When these T cells were transplanted into mice, they also displayed great in vivo therapeutic efficacy against leukemia cells.

An important feature of mLPA is that differently from protein TAA, it does not change its structure, and remains abundant in leukemia cells. The Swiss team is now investigating, whether mLPA can be used to target leukemia cells in addition to protein TAA. This type of immunotherapy may be extremely beneficial in preventing relapses of the disease after chemotherapy and bone marrow transplantation. It opens new avenues to novel non-invasive cancer immunotherapies.

Original source Marco Lepore, Claudia de Lalla, S. Ramanjaneyulu Gundimeda, Heiko Gsellinger, Michela Consonni, Claudio Garavaglia, Sebastiano Sansano, Francesco Piccolo, Andrea Scelfo, Daniel Hussinger, Daniela Montagna, Franco Locatelli, Chiara Bonini, Attilio Bondanza, Alessandra Forcina, Zhiyuan Li, Guanghui Ni, Fabio Ciceri, Paul Jen, Chengfeng Xia, Lucia Mori, Paolo Dellabona, Giulia Casorati, and Gennaro De Libero

Further information Prof. Gennaro De Libero, University of Basel, Department of Biomedicine, phone: +41 61 265 23 65, email: gennaro.delibero@unibas.ch Dr. Lucia Mori, University of Basel, Department of Biomedicine, phone: +41 61 265 23 27, email: lucia.mori@unibas.ch Weitere Informationen:http://www.jem.org/cgi/doi/10.1084/jem.20140410 - Abstract

Continued here:
Lipids Help to Fight Leukemia

LOS ANGELES (KABC) --

Amanda Canale doesn't take time with her daughter and niece for granted. She's just happy to feel good.

"I've been in the hospital, and I've been sick my whole life," Amanda said.

Amanda was born with a rare blood disorder that required daily shots.

"Basically, I have no white blood cells," Amanda said. "I have no immune system at all."

At 23, she developed leukemia and was given two weeks to live. She desperately needed a bone marrow transplant, but family members weren't matches. Her doctor suggested an umbilical cord blood transplant.

"The cord was a perfect match and it was available, so it was the right solution for her," Edward Agura, MD, Medical Director of Bone Marrow Transplantation, Baylor University Medical Center, Dallas, said.

Cord blood contains stem cells that regenerate. Mothers of newborns can save their child's own blood or donate it. More than 30,000 transplants have been performed worldwide. However, because the blood comes from a tiny newborn, there's not much of it.

"The cord blood is rare, precious and few, and yet is more potent in its ability to grow," Dr. Agura said.

Now, doctors at Baylor are treating patients by combining cord blood from multiple donors. They've found this increases the number of stem cells and provides faster recovery. Amanda's transfusion was from a baby whose mother donated six years earlier. The procedure completely cured her cancer and blood disorder.

Follow this link:
Cord blood infusion saves woman's life

Get Breaking News First

Receive News, Politics, and Entertainment Headlines Each Morning.

BOSTON (CBS) Behaylu Barry is on the mend at home in Stratham, New Hampshire, after 34 days at Boston Childrens Hospital.

Behaylu, 13, received a bone marrow transplant in an effort to rebuild his immune system, compromised by a rare blood disorder.

I didnt feel like I had anything at all until I started doing something, said Behaylu of his aplastic anemia, diagnosed in February.

The star athlete scored seven goals in a January soccer game but a week later, felt exhausted and out of breath. Nose bleeds and infected cuts led his parents to believe something was seriously wrong. When doctors told Midori and Aidan Barry that Behaylu would need a bone marrow transplant, it was terrifying to hear.

The reality is we havent had time to think about it. Youre a parent. You go into campaign mode, said Aidan. That campaign lead the Barrys back to a village in Ethiopia where they first met Behaylu in 2007. Then 6-years-old, his biological parents couldnt afford to care for Behaylu so they put him up for adoption. Though the Barrys had three grown children of their own, they brought Behaylu home and eventually began assisting his other siblings still in Africa.

We thought we were helping them. We never thought theyd help us, said Aidan of the familys quick response to the Barrys request for cheek swabs, in an attempt to find a bone marrow donor for Behaylu. Two of his five siblings were perfect matches. Rediat, 16, and Eden, 10, quickly came to the United States.

The trio had two weeks to reconnect, even attending a New England Revolution game when the team was gracious enough to donate box seats. Behaylus compromised immune system makes it dangerous for him to be exposed to crowds.

During the visit, doctors decided Rediat should be the bone marrow donor. The two brothers underwent the painful procedure in May. Behaylu also received chemotherapy. Now his body is building a new immune system with the help of stem cells from Rediat.

Read the original:
NH Teen In Recovery After International Search For Bone Marrow Donor

H-E-B's private label skin care line is the retailers Beauty Pick of the Month.

The formula for EverVescence by H-E-B includes Uttwiler Spatlauber Swiss Apples, which contain stem cells that help reduce the appearance of fine lines, wrinkles and tired skin.

The line includes: Redefining Eye Cream, Redefining Face Serum and Facial Moisturizer with SPF 15.

As the beauty pick of the month, the line is promoted on heb.com and social media.

The Beauty Pick of the Month is also reviewed by members of H-E-B's beauty panel, which includes H-E-B's employees as well as beauty bloggers.

Among the reviews:

"The eye cream is like a spa treatment with a cooling effect that sinks in and feels fabulous, wrote "Cheryl," online editor for heb.com. Now I can pick up my skincare products at my HEB.

Meanwhile, Liz, H-E-Bs digital marketing manager, said she would recommend all three items to others:

"I used all three as directed and found my skin was softer, she said. The smell was light and not unpleasant like other products I have tried. The products did not irritate my sensitive skin.

Read the rest here:
H-E-B promotes store brand skin care line